Search

Interferon(IFN) is an essential component of the treatment of chronic HCV infection and at present, it is the most important to improve its efficacy, not only for HCV chronic liver diseases, but also for the prevention of HCV-associated hepatocellular carcinoma. Two long-acting IFN preparations(PEG-IFN alpha 2a and 2b) have been used at present and clinical studies have shown that sustained virologic, biochemical and histological responder rates are significantly higher in PEG-IFN-treated patients with HCV associated chronic hepatitis and cirrhosis comparing with ones treated with conventional IFN. In addition, PEG-IFN treatment in combination with ribavirin seems to be the best for HCV-associated chronic liver diseases.

Contrast-enhanced ultrasonography (arterial infusion) has been clinically established as a qualitative diagnosis imaging tool for hepatocellular carcinoma (HCC). Contrast-enhanced ultrasonography (CEUS) was performed after of Albunex (sonicated serum albumin) or Carbon Dioxide (CO2) microbubble by hand, into the hepatic artery as a diagnostic modality for the early HCC. Here, we discussed the diagnosis of the early HCC by CEUS using Albunex as a contrast medium. Briefly, a diagnosis of the early HCC was made CEUS examination of the hemodynamics of the arteries showed a hypovascular pattern. And tumor size was under 20 mm in diameter, the histopathologic examination was essential to reach a final diagnosis, well-differentiated HCC.

We investigated the efficacy of retreatment with interferon in patients with chronic hepatitis C who were non responders to the initial interferon treatment. The results were as follows: 1) The effective rate was very low and 2 of the 16 responded to the 2nd treatment. 2) Serum HCV-RNA levels before retreatment with interferon were compared among the 4 responders and the 13 non responders to interferon and it was significantly lower in the 4 responders. 3) HCV-genotypes may be useful to predict the efficacy of interferon readministration.